Companies · Biotechnology

Logical Therapeutics Inc

WALTHAM · Biotechnology

Diligence memoA one-page analyst read on Logical Therapeutics Inc — recommendation, valuation, rhythm, risks.
$42.5M
Total raised · real
2
Rounds
0.3×
Latest step-up
Top 21%
Sector rank · raised
Series B
Latest stage · inferred · Fri May 14 2010 00:00:00 GMT+0000 (Coordinated Universal Time)

Logical Therapeutics Inc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.61× the median modeled value of Series B Biotechnology companies in 2010–2012 (48 peers) — value vs value, same stage and era.
Dormant
  • Last raise 16.1 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Logical Therapeutics Inc is one of 4293 Biotechnology companies tracked from WALTHAM. By capital raised it ranks in the upper tier (ahead of 80% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeries B · 2007-06-11 Raised $33M (real) Modeled valuation $1.3B (est)$33M$1.3BSeries B2007Series B · 2010-05-14 Raised $10M (real) Modeled valuation $397M (est)$10M$397MSeries B2010+$10MCumulative $43M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$32.5M · 2007
Series B extension$10.0M · 2010

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.

Modeled valuation trajectory
$396.9M
Base estimate est.
$20.0M
Conservative case
$1.5B
Upside case
$55.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series B · modeled $1.3B · 2007-06-112007Series B · modeled $396.9M · 2010-05-142010
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
6.0 yr
Elapsed time used
16.1 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
35 mo
Avg between rounds
$14.5M/yr
Capital velocity
19.1 yr
On record since
2007
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 5.9× above median
This company$42.5M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.6× of median
This company$10.0M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 6.2× above median
This company$396.9M
Sector median$64.2M

Raised more than 80% of sector peers (real $). Modeled value above 80% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #33 of 48.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Redpoint Bio CORP · Series B Raised $40.0M · modeled $1.6B (est)Cardiaq Valve Technologies Inc · Series B Raised $77.2M · modeled $1.5B (est)Visterra, Inc. · Series B Raised $82.4M · modeled $1.4B (est)Celltex Therapeutics Corp · Series B Raised $34.1M · modeled $1.4B (est)Crown Bioscience, Inc · Series B Raised $87.1M · modeled $1.2B (est)Trius Therapeutics Inc · Series B Raised $49.3M · modeled $1.2B (est)Intercept Pharmaceuticals Inc · Series B Raised $45.0M · modeled $1.2B (est)Crescendo Bioscience, Inc. · Series B Raised $169.8M · modeled $1.1B (est)Allocure Inc · Series B Raised $50.5M · modeled $1.1B (est)Pathwork Diagnostics Inc · Series B Raised $52.5M · modeled $1.0B (est)MethylGene Inc. · Series B Raised $97.2M · modeled $1.0B (est)Predictive Biosciences, Inc · Series B Raised $26.8M · modeled $1.0B (est)Logical Therapeutics Inc (this company) Raised $42.5M · modeled $396.9M (est)Logical Therapeutics Inc
CompanyStageRaised · realValue · estvs peer med.
Redpoint Bio CORPSeries B$40.0M$1.6B2.44×
Cardiaq Valve Technologies IncSeries B$77.2M$1.5B2.27×
Visterra, Inc.Series B$82.4M$1.4B2.08×
Celltex Therapeutics CorpSeries B$34.1M$1.4B2.07×
Crown Bioscience, IncSeries B$87.1M$1.2B1.86×
Trius Therapeutics IncSeries B$49.3M$1.2B1.84×
Intercept Pharmaceuticals IncSeries B$45.0M$1.2B1.83×
Crescendo Bioscience, Inc.Series B$169.8M$1.1B1.73×
Allocure IncSeries B$50.5M$1.1B1.61×
Pathwork Diagnostics IncSeries B$52.5M$1.0B1.60×
MethylGene Inc.Series B$97.2M$1.0B1.59×
Predictive Biosciences, IncSeries B$26.8M$1.0B1.55×
Logical Therapeutics Inc this companySeries B$42.5M$396.9M0.61×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$32.5M2007-06-11$180.8M$1.3B90%
Series B$10.0M2010-05-14$55.6M$396.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$32.5M2007-06-11
    • First recorded raise — entered as Series B.
  2. Series B$10.0M2010-05-14
    • Raised again after 35 mo — slower than the ~14 mo sector norm.
    • Round 3.3× smaller than the prior — bridge or down round.
Intelligence
2013 ~Q2
Modeled next raise · ~35mo cadence
$10.0M
Modeled next size est.range $10.0M$16.0M
0.3×
Last step-up
$14.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Lutz Giebel5 other2007-06
Bryant Fong4 other2010-05
Martin Edwards4 other2007-06
Paul Schmitt4 other2007-06
CAROLYN GREEN1 other2007-06
PETER LANKAU1 other2007-06
Registry & provenance

Logical Therapeutics Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1405056
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Tarsa Therapeutics, Inc.BiotechnologySeries B$46.8M$21.8Mnetwork1 shared operator · same sector · same stage
Allocure IncBiotechnologySeries B$50.5M$1.1Bnetwork1 shared operator · same sector · same stage
Good Start Genetics, Inc.BiotechnologySeries B$28.2M$396.9Mnetwork1 shared operator · same sector · same stage
Lux Biosciences IncBiotechnologySeries B$81.1M$635.0Mnetwork1 shared operator · same sector · same stage
BioAegis Therapeutics, Inc.BiotechnologySeries B$42.4M$458.4Msame sector · same stage
Applied Genetic Technologies CorpBiotechnologySeries B$42.9M$340.5Msame sector · same stage
Tentarix Biotherapeutics, LPBiotechnologySeries B$43.0M$358.6Msame sector · same stage
Ophthotech Corp.BiotechnologySeries B$43.1M$452.5Msame sector · same stage
Frequently asked
How much funding has Logical Therapeutics Inc raised?
Logical Therapeutics Inc has raised approximately $42.5M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Logical Therapeutics Inc's estimated valuation?
Provath's modeled valuation for Logical Therapeutics Inc is approximately $396.9M (modeled range $20.0M–$1.5B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Logical Therapeutics Inc at?
Logical Therapeutics Inc's latest modeled financing stage is Series B. Its most recent recorded round closed around Fri May 14.
What does Logical Therapeutics Inc do and where is it based?
Logical Therapeutics Inc operates in the Biotechnology sector, based in WALTHAM.
Explore related

See where Logical Therapeutics Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Logical Therapeutics Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.